Breaking News Instant updates and real-time market news.

GNS

Genius Group

$3.52 /

-0.33 (-8.57%)

07:22
03/01/23
03/01
07:22
03/01/23
07:22

Genius Group sues Alto Opportunity, Ayrton Capital, Waqas Khatri

Genius Group announced that on February 27, 2023, the company filed a complaint in the United States District Court Southern District of New York, Case Number 1:23-cv-01639 against Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, Ayrton Capital, LLC and Waqas Khatri seeking an Order that rescinds and declares a financing agreement with Ayrton Capital to be null and void. This lawsuit was filed by Warshaw Burstein LLP of New York and Christian Levine Law Group LLC of Texas, two firms that possess extensive experience and achieved considerable success in litigating stock manipulation cases. The suit challenges multiple aspects of the financing agreement including Ayrton's claim that in exchange for lending $18 million dollars to Genius, it can convert this loan into 49 million ordinary shares of the company worth around $200 million dollars. Genius Group's CEO, Roger Hamilton said that "the company is committed to protecting the integrity of its operations and the value of its shareholders equity by investigating and prosecuting toxic lenders, and market manipulators who violate federal securities laws."

  • 12

    Apr

OTHER BREAKING NEWS FROM THE FLY

General news
Market Update: » 02:45
03/21/23
03/21
02:45
03/21/23
02:45
$ECON

Economic Data

/

+

Market Update: Investor…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Periodicals
Treasury considering expanding FDIC coverage to all deposits, Bloomberg reports » 20:56
03/20/23
03/20
20:56
03/20/23
20:56
SPY

SPDR S&P 500 ETF Trust

$393.67 /

+3.55 (+0.91%)

, SPX

S&P 500

/

+

, QQQ

Invesco QQQ Trust

$305.90 /

+1.0522 (+0.35%)

, KRE

SPDR S&P Regional Banking ETF

$43.60 /

+0.17 (+0.39%)

, XLF

Financial Select Sector

$31.18 /

+0.235 (+0.76%)

The U.S. Treasury…

The U.S. Treasury Department is looking into whether the federal regulators are able to insure banking deposits beyond the current $250K FDIC cap, Bloomberg's Saleha Mohsin and Sridhar Natarajan report, citing people familiar with discussions. The report states that the emergency authority is being sought by a coalition of banks, claiming that it is needed to prevent a potential financial crisis. Under one legal framework that is being considered for expanding FDIC insurance, regulators would use the Treasury Department's authority to take emergency action and lean on the Exchange Stabilization Fund. Reference Link

ShowHide Related Items >><<
SPY SPDR S&P 500 ETF Trust
$393.67 /

+3.55 (+0.91%)

SPX S&P 500
/

+

QQQ Invesco QQQ Trust
$305.90 /

+1.0522 (+0.35%)

KRE SPDR S&P Regional Banking ETF
$43.60 /

+0.17 (+0.39%)

SPY SPDR S&P 500 ETF Trust
$393.67 /

+3.55 (+0.91%)

03/20/23 Citi
Citi sees 25 basis point hike from Fed on Wednesday
03/17/23 JPMorgan
JPMorgan expects 25 point hike from Federal Reserve next week
03/07/23 JPMorgan
JPMorgan says 'spooked' Powell opened door to 50 point hike
02/13/23 JPMorgan
Stock market risk/reward 'skewed to the downside,' says JPMorgan
SPX S&P 500
/

+

QQQ Invesco QQQ Trust
$305.90 /

+1.0522 (+0.35%)

04/25/22 Gordon Haskett
Twitter bid more attractive after market selloff, says Gordon Haskett
KRE SPDR S&P Regional Banking ETF
$43.60 /

+0.17 (+0.39%)

XLF Financial Select Sector
$31.18 /

+0.235 (+0.76%)

SPY SPDR S&P 500 ETF Trust
$393.67 /

+3.55 (+0.91%)

QQQ Invesco QQQ Trust
$305.90 /

+1.0522 (+0.35%)

SPY SPDR S&P 500 ETF Trust
$393.67 /

+3.55 (+0.91%)

XLF Financial Select Sector
$31.18 /

+0.235 (+0.76%)

SPX S&P 500
/

+

QQQ Invesco QQQ Trust
$305.90 /

+1.0522 (+0.35%)

KRE SPDR S&P Regional Banking ETF
$43.60 /

+0.17 (+0.39%)

XLF Financial Select Sector
$31.18 /

+0.235 (+0.76%)

SPY SPDR S&P 500 ETF Trust
$393.67 /

+3.55 (+0.91%)

QQQ Invesco QQQ Trust
$305.90 /

+1.0522 (+0.35%)

Recommendations
Lennar price target raised to $123 from $113 at Citi » 20:51
03/20/23
03/20
20:51
03/20/23
20:51
LEN

Lennar

$102.25 /

-1.23 (-1.19%)

Citi analyst Anthony…

Citi analyst Anthony Pettinari raised the firm's price target on Lennar to $123 from $113 and keeps a Buy rating on the shares. Citing "encouraging" quarter-to-date trends, the analyst increased estimates for the firm's builder coverage. Citi sees strong spring demand for the sector.

ShowHide Related Items >><<
LEN Lennar
$102.25 /

-1.23 (-1.19%)

LEN Lennar
$102.25 /

-1.23 (-1.19%)

03/17/23 RBC Capital
Lennar price target raised to $85 from $76 at RBC Capital
03/16/23 BTIG
Lennar price target raised to $120 from $116 at BTIG
03/16/23 Credit Suisse
Lennar price target raised to $96 from $88 at Credit Suisse
03/01/23 Oppenheimer
Lennar initiated with a Perform at Oppenheimer
LEN Lennar
$102.25 /

-1.23 (-1.19%)

LEN Lennar
$102.25 /

-1.23 (-1.19%)

LEN Lennar
$102.25 /

-1.23 (-1.19%)

Recommendations
Bechtle price target raised to EUR 53 from EUR 51 at Jefferies » 20:43
03/20/23
03/20
20:43
03/20/23
20:43
BECTY

Bechtle

$7.89 /

+ (+0.00%)

Jefferies analyst Martin…

Jefferies analyst Martin Comtesse raised the firm's price target on Bechtle to EUR 53 from EUR 51 and keeps a Buy rating on the shares. The company's FY22 results and outlook for 5%-10% growth in top- and bottom line provided a "reassuring message" that IT budgets remain robust and supply continues to improve, the analyst tells investors in a research note.

ShowHide Related Items >><<
BECTY Bechtle
$7.89 /

+ (+0.00%)

01/24/23 Deutsche Bank
Bechtle price target raised to EUR 53 from EUR 52 at Deutsche Bank
11/28/22 BofA
Bechtle initiated with a Neutral at BofA
11/21/22 Exane BNP Paribas
Bechtle downgraded to Neutral from Outperform at Exane BNP Paribas
11/14/22 Berenberg
Bechtle price target lowered to EUR 43 from EUR 47 at Berenberg
Hot Stocks
Cathie Wood's ARK Investment bought 424.7K shares of Cerus today  20:31
03/20/23
03/20
20:31
03/20/23
20:31
CERS

Cerus

$2.90 /

-0.02 (-0.68%)

 
ShowHide Related Items >><<
CERS Cerus
$2.90 /

-0.02 (-0.68%)

CERS Cerus
$2.90 /

-0.02 (-0.68%)

01/20/23 BTIG
Cerus downgraded to Neutral from Buy at BTIG
CERS Cerus
$2.90 /

-0.02 (-0.68%)

CERS Cerus
$2.90 /

-0.02 (-0.68%)

Hot Stocks
Cathie Wood's ARK Investment bought 41K shares of Microsoft today  20:30
03/20/23
03/20
20:30
03/20/23
20:30
MSFT

Microsoft

$272.20 /

-7.21 (-2.58%)

 
ShowHide Related Items >><<
MSFT Microsoft
$272.20 /

-7.21 (-2.58%)

MSFT Microsoft
$272.20 /

-7.21 (-2.58%)

03/20/23 Stifel
Alphabet resumed with a Buy at Stifel
03/20/23 Evercore ISI
Microsoft price target raised to $295 from $280 at Evercore ISI
03/17/23 Mizuho
Microsoft price target raised to $315 from $300 at Mizuho
03/16/23 Macquarie
Microsoft 'clear winner' in ongoing generative AI fight, says Macquarie
MSFT Microsoft
$272.20 /

-7.21 (-2.58%)

MSFT Microsoft
$272.20 /

-7.21 (-2.58%)

MSFT Microsoft
$272.20 /

-7.21 (-2.58%)

MSFT Microsoft
$272.20 /

-7.21 (-2.58%)

Hot Stocks
Cathie Wood's ARK Investment bought 181K shares of Teladoc today  20:30
03/20/23
03/20
20:30
03/20/23
20:30
TDOC

Teladoc

$24.37 /

-0.185 (-0.75%)

 
ShowHide Related Items >><<
TDOC Teladoc
$24.37 /

-0.185 (-0.75%)

TDOC Teladoc
$24.37 /

-0.185 (-0.75%)

03/10/23 Credit Suisse
Teladoc price target lowered to $27 from $30 at Credit Suisse
03/06/23 Canaccord
Teladoc price target lowered to $36 from $40 at Canaccord
03/06/23 Wells Fargo
Teladoc price target lowered to $23 from $28 at Wells Fargo
02/27/23 Deutsche Bank
Teladoc price target lowered to $27 from $31 at Deutsche Bank
TDOC Teladoc
$24.37 /

-0.185 (-0.75%)

TDOC Teladoc
$24.37 /

-0.185 (-0.75%)

TDOC Teladoc
$24.37 /

-0.185 (-0.75%)

TDOC Teladoc
$24.37 /

-0.185 (-0.75%)

Hot Stocks
Enovix director buys $757K in common stock » 20:28
03/20/23
03/20
20:28
03/20/23
20:28
ENVX

Enovix

$10.83 /

-0.4 (-3.56%)

In a regulatory filing,…

In a regulatory filing, Enovix disclosed that its director Thurman Rodgers bought 69.6K shares of common stock on March 20th in a total transaction size of $757.

ShowHide Related Items >><<
ENVX Enovix
$10.83 /

-0.4 (-3.56%)

ENVX Enovix
$10.83 /

-0.4 (-3.56%)

02/23/23 Craig-Hallum
Enovix price target lowered to $15 from $23 at Craig-Hallum
02/23/23 Piper Sandler
Enovix price target raised to $25 from $22.50 at Piper Sandler
01/26/23 JPMorgan
Enovix price target lowered to $16 from $28 at JPMorgan
01/23/23 Piper Sandler
Enovix price target lowered to $22.50 from $26.50 at Piper Sandler
ENVX Enovix
$10.83 /

-0.4 (-3.56%)

ENVX Enovix
$10.83 /

-0.4 (-3.56%)

ENVX Enovix
$10.83 /

-0.4 (-3.56%)

Hot Stocks
Snap COO sells $763.9K in common stock » 19:09
03/20/23
03/20
19:09
03/20/23
19:09
SNAP

Snap

$10.65 /

-0.045 (-0.42%)

In a regulatory filing,…

In a regulatory filing, Snap disclosed that its COO Jerry Hunter sold 69.8K shares of common stock on March 16th in a total transaction size of $763.9K.

ShowHide Related Items >><<
SNAP Snap
$10.65 /

-0.045 (-0.42%)

SNAP Snap
$10.65 /

-0.045 (-0.42%)

03/16/23 Benchmark
Benchmark sees low odds of any formal TikTok ban in U.S. through 2024
03/09/23 Piper Sandler
Piper says TikTok ownership change would have negligible value impact on peers
02/14/23 BofA
Snap analyst day an opportunity to reset targets, says BofA
02/01/23 Truist
Snap price target lowered to $8 from $10 at Truist
SNAP Snap
$10.65 /

-0.045 (-0.42%)

SNAP Snap
$10.65 /

-0.045 (-0.42%)

SNAP Snap
$10.65 /

-0.045 (-0.42%)

SNAP Snap
$10.65 /

-0.045 (-0.42%)

Hot Stocks
Snap CFO sells $539K in common stock » 19:08
03/20/23
03/20
19:08
03/20/23
19:08
SNAP

Snap

$10.65 /

-0.045 (-0.42%)

In a regulatory filing,…

In a regulatory filing, Snap disclosed that its CFO Derek Andersen sold 49.2K shares of common stock on March 16th in a total transaction size of $539.2K.

ShowHide Related Items >><<
SNAP Snap
$10.65 /

-0.045 (-0.42%)

SNAP Snap
$10.65 /

-0.045 (-0.42%)

03/16/23 Benchmark
Benchmark sees low odds of any formal TikTok ban in U.S. through 2024
03/09/23 Piper Sandler
Piper says TikTok ownership change would have negligible value impact on peers
02/14/23 BofA
Snap analyst day an opportunity to reset targets, says BofA
02/01/23 Truist
Snap price target lowered to $8 from $10 at Truist
SNAP Snap
$10.65 /

-0.045 (-0.42%)

SNAP Snap
$10.65 /

-0.045 (-0.42%)

SNAP Snap
$10.65 /

-0.045 (-0.42%)

SNAP Snap
$10.65 /

-0.045 (-0.42%)

Recommendations
Pinduoduo price target lowered to $115 from $127 at Citi » 18:50
03/20/23
03/20
18:50
03/20/23
18:50
PDD

Pinduoduo

$78.90 /

-13.01 (-14.16%)

Citi lowered the…

Citi lowered the firm's price target on Pinduoduo to $115 from $127 but keeps a Buy rating on the shares. The analyst states that considering the challenging macro and COVID-disrupted Q4, the 38% growth in online marketing revenue and 86% growth in commission fee revenue that drove the 43% growth in profit are stronger than the company's peers. Citi warns however that the higher base and higher expenses related to fast expansion plans of Temu are likely to weigh on Pinduoduo margins.

ShowHide Related Items >><<
PDD Pinduoduo
$78.90 /

-13.01 (-14.16%)

PDD Pinduoduo
$78.90 /

-13.01 (-14.16%)

03/02/23 Morgan Stanley
Pinduoduo upgraded to Overweight from Equal Weight at Morgan Stanley
12/09/22 KGI Securities
Pinduoduo upgraded to Outperform from Neutral at KGI Securities
11/30/22 Barclays
Pinduoduo price target raised to $84 from $70 at Barclays
11/29/22 Benchmark
Pinduoduo price target raised to $112 from $107 at Benchmark
PDD Pinduoduo
$78.90 /

-13.01 (-14.16%)

PDD Pinduoduo
$78.90 /

-13.01 (-14.16%)

PDD Pinduoduo
$78.90 /

-13.01 (-14.16%)

PDD Pinduoduo
$78.90 /

-13.01 (-14.16%)

Recommendations
MacroGenics price target raised to $12 from $6 at BTIG » 18:47
03/20/23
03/20
18:47
03/20/23
18:47
MGNX

MacroGenics

$6.70 /

+0.05 (+0.75%)

BTIG analyst Kaveri…

BTIG analyst Kaveri Pohlman raised the firm's price target on MacroGenics to $12 from $6 and keeps a Buy rating on the shares. The firm said that small modifications to both MGD024 and lorigerlimab increases its interest in the pipeline. BTIG added that it raised its price target on better visibility into MGC018's commercial opportunity.

ShowHide Related Items >><<
MGNX MacroGenics
$6.70 /

+0.05 (+0.75%)

MGNX MacroGenics
$6.70 /

+0.05 (+0.75%)

03/20/23 Citi
MacroGenics price target raised to $8 from $7 at Citi
03/20/23 H.C. Wainwright
MacroGenics price target raised to $14 from $12 at H.C. Wainwright
03/17/23 Guggenheim
MacroGenics downgraded to Neutral at Guggenheim on prostate cancer caution
03/17/23 Guggenheim
MacroGenics downgraded to Neutral from Buy at Guggenheim
MGNX MacroGenics
$6.70 /

+0.05 (+0.75%)

MGNX MacroGenics
$6.70 /

+0.05 (+0.75%)

Recommendations
WeWork price target lowered to $3 from $7.50 at BTIG » 18:46
03/20/23
03/20
18:46
03/20/23
18:46
WE

WeWork

$1.01 /

+0.0348 (+3.57%)

BTIG analyst Thomas…

BTIG analyst Thomas Catherwood lowered the firm's price target on WeWork to $3 from $7.50 and keeps a Buy rating on the shares. The firm said that dilution is painful, but it views recapitalization as a vote of confidence.

ShowHide Related Items >><<
WE WeWork
$1.01 /

+0.0348 (+3.57%)

WE WeWork
$1.01 /

+0.0348 (+3.57%)

02/16/23 Piper Sandler
WeWork shares should outperform on results, says Piper Sandler
01/03/23 BTIG
WeWork named Top Pick for first half of 2023 at BTIG
12/21/22 Cantor Fitzgerald
WeWork weakness an attractive buying opportunity, says Cantor Fitzgerald
11/04/22 BTIG
WeWork initiated with a Buy at BTIG
WE WeWork
$1.01 /

+0.0348 (+3.57%)

WE WeWork
$1.01 /

+0.0348 (+3.57%)

WE WeWork
$1.01 /

+0.0348 (+3.57%)

WE WeWork
$1.01 /

+0.0348 (+3.57%)

Periodicals
Judge says JPMorgan, Deutsche will have to face Epstein lawsuits, Reuters says » 18:29
03/20/23
03/20
18:29
03/20/23
18:29
JPM

JPMorgan

$127.09 /

+1.32 (+1.05%)

, DB

Deutsche Bank

$9.92 /

+0.03 (+0.30%)

U.S. District Judge Jed…

U.S. District Judge Jed Rakoff in Manhattan determined that JPMorgan (JPM) and Deutsche Bank (DB) will have to face lawsuits accusing the banks of enabling Jeffrey Epstein's sex trafficking, Reuters' Jonathan Stempel reports. The decision could expose the two lenders to additional financial and reputational damage for maintaining Epstein as a client, the author notes. In his order, Rakoff said JPMorgan must face a lawsuit by the U.S. Virgin Islands that claims the bank missed red flags about Epstein's abuse of women on Little St. James, the author says, noting that the judge also ruled both companies must face proposed class actions by women who said Epstein abused them. Reference Link

ShowHide Related Items >><<
JPM JPMorgan
$127.09 /

+1.32 (+1.05%)

DB Deutsche Bank
$9.92 /

+0.03 (+0.30%)

JPM JPMorgan
$127.09 /

+1.32 (+1.05%)

03/13/23 Wells Fargo
Wells Fargo upgrades JPMorgan on 'Goliath is Winning' theme
03/13/23 Wells Fargo
JPMorgan upgraded to Overweight from Equal Weight at Wells Fargo
02/24/23 Morgan Stanley
JPMorgan price target raised to $173 from $167 at Morgan Stanley
02/08/23 Keefe Bruyette
Keefe Bruyette downgrades 'vulnerable' Bank of America to Underperform
DB Deutsche Bank
$9.92 /

+0.03 (+0.30%)

02/10/23 BofA
Deutsche Bank downgraded to Underperform from Neutral at BofA
02/08/23 UBS
Deutsche Bank price target raised to EUR 18.80 from EUR 16.30 at UBS
02/03/23 Credit Suisse
Deutsche Bank price target raised to EUR 11 from EUR 10.50 at Credit Suisse
01/13/23 Barclays
Deutsche Bank price target raised to EUR 12.50 from EUR 11.50 at Barclays
JPM JPMorgan
$127.09 /

+1.32 (+1.05%)

DB Deutsche Bank
$9.92 /

+0.03 (+0.30%)

JPM JPMorgan
$127.09 /

+1.32 (+1.05%)

DB Deutsche Bank
$9.92 /

+0.03 (+0.30%)

JPM JPMorgan
$127.09 /

+1.32 (+1.05%)

DB Deutsche Bank
$9.92 /

+0.03 (+0.30%)

JPM JPMorgan
$127.09 /

+1.32 (+1.05%)

DB Deutsche Bank
$9.92 /

+0.03 (+0.30%)

Hot Stocks
Broadcom CEO sells $18.8M in common stock » 18:26
03/20/23
03/20
18:26
03/20/23
18:26
AVGO

Broadcom

$643.63 /

+13.22 (+2.10%)

In a regulatory filing,…

In a regulatory filing, Broadcom disclosed that its CEO Hock Tan sold 30K shares of common stock on March 16th in a total transaction size of $18.8M.

ShowHide Related Items >><<
AVGO Broadcom
$643.63 /

+13.22 (+2.10%)

AVGO Broadcom
$643.63 /

+13.22 (+2.10%)

03/03/23 OTR Global
Qualcomm displacing Broadcom for S23 components, says OTR Global
03/03/23 Truist
Broadcom price target raised to $700 from $659 at Truist
03/03/23 Susquehanna
Broadcom price target raised to $690 from $685 at Susquehanna
03/03/23 TD Cowen
Broadcom price target raised to $615 from $540 at TD Cowen
AVGO Broadcom
$643.63 /

+13.22 (+2.10%)

AVGO Broadcom
$643.63 /

+13.22 (+2.10%)

AVGO Broadcom
$643.63 /

+13.22 (+2.10%)

AVGO Broadcom
$643.63 /

+13.22 (+2.10%)

Hot Stocks
First Majestic falls 17% after announcing cost cuts, suspended mining activity  18:25
03/20/23
03/20
18:25
03/20/23
18:25
AG

First Majestic

$7.44 /

+0.12 (+1.64%)

 
ShowHide Related Items >><<
AG First Majestic
$7.44 /

+0.12 (+1.64%)

AG First Majestic
$7.44 /

+0.12 (+1.64%)

02/27/23 TD Securities
First Majestic price target lowered to C$11 from C$12 at TD Securities
02/14/23 National Bank
First Majestic price target lowered to C$11 from C$14.50 at National Bank
01/20/23 BMO Capital
First Majestic price target lowered to C$9 from C$10.50 at BMO Capital
01/13/23 National Bank
First Majestic price target raised to C$14.50 from C$13 at National Bank
AG First Majestic
$7.44 /

+0.12 (+1.64%)

Hot Stocks
RA Capital reports 9.99% passive stake in Orchard Therapeutics » 18:22
03/20/23
03/20
18:22
03/20/23
18:22
ORTX

Orchard Therapeutics

$4.76 /

+0.16 (+3.48%)

RA Capital disclosed a…

RA Capital disclosed a 9.99% stake in Orchard Therapeutics, which represents over 18.56M shares. The filing does not allow for activism. Shares of Orchard Therapeutics are up 5.2% afterhours.

ShowHide Related Items >><<
ORTX Orchard Therapeutics
$4.76 /

+0.16 (+3.48%)

ORTX Orchard Therapeutics
$4.76 /

+0.16 (+3.48%)

03/15/23 Stifel
Orchard Therapeutics target adjusted to $22 at Stifel after ADS ratio change
03/13/23 Oppenheimer
Orchard Therapeutics price target raised to $37 from $5 at Oppenheimer
07/18/22 Oppenheimer
Orchard Therapeutics assumed with an Outperform at Oppenheimer
05/13/22 Barclays
Orchard Therapeutics price target lowered to $4 from $6 at Barclays
ORTX Orchard Therapeutics
$4.76 /

+0.16 (+3.48%)

ORTX Orchard Therapeutics
$4.76 /

+0.16 (+3.48%)

Hot Stocks
Canadian National, Unifor reach tentative agreements » 18:02
03/20/23
03/20
18:02
03/20/23
18:02
CNI

Canadian National

$115.34 /

+0.1 (+0.09%)

Canadian National…

Canadian National announced that new tentative collective agreements have been reached between Unifor and CN. The collective agreements cover approximately 3,000 CN employees working in various departments such as Mechanical, Intermodal, Facility Management, and in clerical positions in Canada. No details of the tentative agreements will be released publicly until the agreements are ratified.

ShowHide Related Items >><<
CNI Canadian National
$115.34 /

+0.1 (+0.09%)

CNI Canadian National
$115.34 /

+0.1 (+0.09%)

01/25/23 Desjardins
Canadian National price target lowered to C$179 from C$180 at Desjardins
01/25/23 CIBC
Canadian National price target lowered to C$175 from C$181 at CIBC
01/25/23 BMO Capital
Canadian National price target lowered to C$180 from C$185 at BMO Capital
01/25/23 Scotiabank
Canadian National price target lowered to C$167 from C$170 at Scotiabank
CNI Canadian National
$115.34 /

+0.1 (+0.09%)

CNI Canadian National
$115.34 /

+0.1 (+0.09%)

CNI Canadian National
$115.34 /

+0.1 (+0.09%)

Periodicals
Thermo Fisher, Celltrion compete for Baxter's biopharma unit, Reuters says » 18:02
03/20/23
03/20
18:02
03/20/23
18:02
TMO

Thermo Fisher

$550.60 /

+3.39 (+0.62%)

, BAX

Baxter

$38.22 /

+0.64 (+1.70%)

, KKR

KKR

$48.63 /

+0.175 (+0.36%)

, CG

Carlyle Group

$30.29 /

-0.14 (-0.46%)

The biopharma solutions…

The biopharma solutions business of medical device maker Baxter International (BAX), is being courted by U.S. scientific instruments maker Thermo Fisher Scientific (TMO) and South Korea's Celltrion, writes Reuter's Anirban Sen and David Carnevali. "The divestment, which the sources said could fetch more than $4B, would help Baxter pay down debt following its $10.5B acquisition of medical device maker Hill-Rom Holdings in 2021 Other suitors for the Baxter unit include KKR & Co (KKR) and Carlyle Group (CG), added the story. Reference Link

ShowHide Related Items >><<
TMO Thermo Fisher
$550.60 /

+3.39 (+0.62%)

KKR KKR
$48.63 /

+0.175 (+0.36%)

CG Carlyle Group
$30.29 /

-0.14 (-0.46%)

BAX Baxter
$38.22 /

+0.64 (+1.70%)

TMO Thermo Fisher
$550.60 /

+3.39 (+0.62%)

03/10/23 Chardan
Gensight Biologics price target lowered to EUR 13 from EUR 15 at Chardan
02/06/23 Jefferies
Jefferies says Catalent could be valued near $93 on average CDMO buyout multiple
02/02/23 Morgan Stanley
Thermo Fisher price target raised to $670 from $613 at Morgan Stanley
02/02/23 TD Cowen
Thermo Fisher price target raised to $711 from $690 at Cowen
BAX Baxter
$38.22 /

+0.64 (+1.70%)

02/13/23 Barclays
Baxter price target lowered to $54 from $63 at Barclays
02/10/23 TD Cowen
Baxter price target lowered to $45 from $70 at Cowen
02/06/23 KeyBanc
Baxter price target lowered to $60 from $73 at KeyBanc
02/01/23 Piper Sandler
Miromatrix MiroliverELAP timeline pushed out two or three quarters, says Piper
KKR KKR
$48.63 /

+0.175 (+0.36%)

03/02/23 Barclays
KKR initiated with an Overweight at Barclays
02/08/23 Deutsche Bank
KKR price target raised to $70 from $67 at Deutsche Bank
02/08/23 Wells Fargo
KKR price target raised to $65 from $59 at Wells Fargo
02/08/23 JMP Securities
KKR price target raised to $80 from $72 at JMP Securities
CG Carlyle Group
$30.29 /

-0.14 (-0.46%)

03/02/23 Barclays
Carlyle Group initiated with an Overweight at Barclays
02/08/23 Deutsche Bank
Carlyle Group price target raised to $43 from $41 at Deutsche Bank
02/08/23 Piper Sandler
Carlyle Group price target lowered to $48 from $58 at Piper Sandler
01/31/23 BMO Capital
Franklin Resources price target raised to $23 from $22 at BMO Capital
TMO Thermo Fisher
$550.60 /

+3.39 (+0.62%)

KKR KKR
$48.63 /

+0.175 (+0.36%)

CG Carlyle Group
$30.29 /

-0.14 (-0.46%)

BAX Baxter
$38.22 /

+0.64 (+1.70%)

TMO Thermo Fisher
$550.60 /

+3.39 (+0.62%)

KKR KKR
$48.63 /

+0.175 (+0.36%)

CG Carlyle Group
$30.29 /

-0.14 (-0.46%)

TMO Thermo Fisher
$550.60 /

+3.39 (+0.62%)

KKR KKR
$48.63 /

+0.175 (+0.36%)

CG Carlyle Group
$30.29 /

-0.14 (-0.46%)

BAX Baxter
$38.22 /

+0.64 (+1.70%)

TMO Thermo Fisher
$550.60 /

+3.39 (+0.62%)

KKR KKR
$48.63 /

+0.175 (+0.36%)

BAX Baxter
$38.22 /

+0.64 (+1.70%)

On The Fly
Fly Intel: After-Hours Movers » 17:59
03/20/23
03/20
17:59
03/20/23
17:59
LTRN

Lantern Pharma

$4.62 /

-0.045 (-0.97%)

, HLIT

Harmonic

$13.11 /

+0.72 (+5.81%)

, PET

Wag! Group

$1.86 /

-0.19 (-9.27%)

, NNDM

Nano Dimension

$2.58 /

-0.03 (-1.15%)

, FUSN

Fusion Pharmaceuticals

$4.00 /

-0.05 (-1.23%)

, VTYX

Ventyx Biosciences

$37.83 /

+1.175 (+3.21%)

Check out this evening's…

ShowHide Related Items >><<
VTYX Ventyx Biosciences
$37.83 /

+1.175 (+3.21%)

PET Wag! Group
$1.86 /

-0.19 (-9.27%)

NNDM Nano Dimension
$2.58 /

-0.03 (-1.15%)

LTRN Lantern Pharma
$4.62 /

-0.045 (-0.97%)

HLIT Harmonic
$13.11 /

+0.72 (+5.81%)

FUSN Fusion Pharmaceuticals
$4.00 /

-0.05 (-1.23%)

LTRN Lantern Pharma
$4.62 /

-0.045 (-0.97%)

10/31/22 EF Hutton
Lantern Pharma initiated with a Buy at EF Hutton
HLIT Harmonic
$13.11 /

+0.72 (+5.81%)

02/08/23 Jefferies
Jefferies reveals top broadband plays, sees 5 years of strong growth
01/31/23 Barclays
Harmonic price target raised to $20 from $17 at Barclays
01/09/23 Jefferies
Harmonic upgraded to Buy from Hold at Jefferies
01/09/23 Jefferies
Harmonic upgraded to Buy from Hold at Jefferies
PET Wag! Group
$1.86 /

-0.19 (-9.27%)

11/21/22 Oppenheimer
Wag! Group initiated with an Outperform at Oppenheimer
11/14/22 DA Davidson
Wag! Group price target lowered to $6.50 from $11 at DA Davidson
10/17/22 Roth MKM
Wag! Group initiated with a Buy at Roth Capital
10/14/22 Craig-Hallum
Wag! Group initiated with a Buy at Craig-Hallum
NNDM Nano Dimension
$2.58 /

-0.03 (-1.15%)

03/10/23 Lake Street
Nano Dimension made 'lowball offer' Stratasys won't accept, says Lake Street
FUSN Fusion Pharmaceuticals
$4.00 /

-0.05 (-1.23%)

12/01/22 B. Riley
Fusion Pharmaceuticals resumed with a Buy at B. Riley
11/30/22 SVB Securities
Fusion Pharmaceuticals initiated with an Outperform at SVB Securities
09/15/22 Truist
Truist starts Fusion Pharmaceuticals at Buy with $10 price target
09/15/22 Truist
Fusion Pharmaceuticals initiated with a Buy at Truist
VTYX Ventyx Biosciences
$37.83 /

+1.175 (+3.21%)

03/20/23 Wells Fargo
Wells starts Ventyx at Overweight, sees multiple catalysts in next 12-18 months
03/20/23 Wells Fargo
Ventyx Biosciences initiated with an Overweight at Wells Fargo
03/20/23 Oppenheimer
Ventyx Biosciences price target raised to $65 from $60 at Oppenheimer
01/31/23 Canaccord
Ventyx Biosciences price target raised to $54 from $35 at Canaccord
VTYX Ventyx Biosciences
$37.83 /

+1.175 (+3.21%)

PET Wag! Group
$1.86 /

-0.19 (-9.27%)

NNDM Nano Dimension
$2.58 /

-0.03 (-1.15%)

LTRN Lantern Pharma
$4.62 /

-0.045 (-0.97%)

HLIT Harmonic
$13.11 /

+0.72 (+5.81%)

FUSN Fusion Pharmaceuticals
$4.00 /

-0.05 (-1.23%)

NNDM Nano Dimension
$2.58 /

-0.03 (-1.15%)

VTYX Ventyx Biosciences
$37.83 /

+1.175 (+3.21%)

PET Wag! Group
$1.86 /

-0.19 (-9.27%)

NNDM Nano Dimension
$2.58 /

-0.03 (-1.15%)

HLIT Harmonic
$13.11 /

+0.72 (+5.81%)

NNDM Nano Dimension
$2.58 /

-0.03 (-1.15%)

Hot Stocks
Moody's upgrades Tesla's credit rating, declares outlook stable » 17:48
03/20/23
03/20
17:48
03/20/23
17:48
TSLA

Tesla

$183.22 /

+3.175 (+1.76%)

Moody's Investors…

Moody's Investors Service assigned a Baa3 long-term issuer rating to Tesla and withdrew the Ba1 corporate family rating, the Ba1-PD probability of default rating, as well as the SGL-1 speculative grade liquidity rating. The outlook is stable. The rating action reflects Moody's expectation that "Tesla will remain one of the foremost manufacturers of battery electric vehicles with an expanding global presence and very high profitability." The upgrade also incorporates governance considerations, including Tesla's prudent financial policy and management's operational track record. Reference Link

ShowHide Related Items >><<
TSLA Tesla
$183.22 /

+3.175 (+1.76%)

TSLA Tesla
$183.22 /

+3.175 (+1.76%)

03/20/23 Morgan Stanley
XPeng price target raised to $12.50 from $12 at Morgan Stanley
03/20/23 Morgan Stanley
Li Auto price target raised to $30 from $23 at Morgan Stanley
03/13/23 Wolfe Research
Tesla downgraded to Peer Perform from Outperform at Wolfe Research
03/09/23 Morgan Stanley
Morgan Stanley questions if Tesla has 'outgrown the Cybertruck'
TSLA Tesla
$183.22 /

+3.175 (+1.76%)

TSLA Tesla
$183.22 /

+3.175 (+1.76%)

TSLA Tesla
$183.22 /

+3.175 (+1.76%)

TSLA Tesla
$183.22 /

+3.175 (+1.76%)

Hot Stocks
Charles Schwab director buys $200K in common stock » 17:47
03/20/23
03/20
17:47
03/20/23
17:47
SCHW

Charles Schwab

$56.09 /

-0.28 (-0.50%)

In a regulatory filing,…

In a regulatory filing, Charles Schwab disclosed that its director Gerri Martin-Flickinger bought bought 3.7K shares of common stock on March 17th in a total transaction size of $200.4K.

ShowHide Related Items >><<
SCHW Charles Schwab
$56.09 /

-0.28 (-0.50%)

SCHW Charles Schwab
$56.09 /

-0.28 (-0.50%)

03/15/23 Credit Suisse
Charles Schwab upgraded to Outperform from Neutral at Credit Suisse
03/14/23 JPMorgan
Schwab funding concerns 'significantly de-risked,' says JPMorgan
03/14/23 Piper Sandler
Charles Schwab price target lowered to $95 from $100 at Piper Sandler
03/14/23 Deutsche Bank
Charles Schwab price target lowered to $83 from $109 at Deutsche Bank
SCHW Charles Schwab
$56.09 /

-0.28 (-0.50%)

  • 10
    Mar
  • 02
    Aug
SCHW Charles Schwab
$56.09 /

-0.28 (-0.50%)

SCHW Charles Schwab
$56.09 /

-0.28 (-0.50%)

SCHW Charles Schwab
$56.09 /

-0.28 (-0.50%)

Periodicals
Goldman tells Reuters Credit Suisse AT1 move could cut long-term demand » 17:44
03/20/23
03/20
17:44
03/20/23
17:44
GS

Goldman Sachs

$309.52 /

+6.13 (+2.02%)

, CS

Credit Suisse

/

+

Goldman Sachs (GS) chief…

Goldman Sachs (GS) chief credit strategist Lotfi Karoui told Reuters that the decision by Swiss authorities to clear out Credit Suisse's (CS) Additional Tier 1 bonds could lower demand for this type of bond in the long term, though a risk of contagion across credit markets was limited due to the relatively niche nature of the bond. The AT1 sell-off was a "knee jerk reaction to an outcome that took a lot of people by surprise," Karoui said, adding, "In the long term, we are a little concerned about the potential permanent destruction in demand ... I do think that investors will have to re-assess how the risk-reward looks like in those instruments, particularly at times of rising financial distress." Reference Link

ShowHide Related Items >><<
GS Goldman Sachs
$309.52 /

+6.13 (+2.02%)

CS Credit Suisse
/

+

GS Goldman Sachs
$309.52 /

+6.13 (+2.02%)

03/09/23 BofA
Goldman Sachs price target raised to $425 from $384 at BofA
03/02/23 Seaport Global
Goldman remains a top pick at Seaport after investor day
03/01/23 Jefferies
Jefferies keeps Buy on Goldman Sachs, says 'questions remain' after investor day
02/27/23 Morgan Stanley
Morgan Stanley not expecting new return targets at Goldman investor day
CS Credit Suisse
/

+

03/20/23 Barclays
European Banks sector view downgraded to Neutral at Barclays
03/20/23 Societe Generale
UBS downgraded to Hold from Buy at Societe Generale
03/20/23 BofA
UBS upgraded to Buy from Neutral at BofA
03/16/23 JPMorgan
Credit Suisse gets short-term relief, but questions remain, says JPMorgan
GS Goldman Sachs
$309.52 /

+6.13 (+2.02%)

CS Credit Suisse
/

+

GS Goldman Sachs
$309.52 /

+6.13 (+2.02%)

CS Credit Suisse
/

+

GS Goldman Sachs
$309.52 /

+6.13 (+2.02%)

CS Credit Suisse
/

+

GS Goldman Sachs
$309.52 /

+6.13 (+2.02%)

CS Credit Suisse
/

+

Hot Stocks
Sigmatron International discloses Event of Default from on credit agreement » 17:39
03/20/23
03/20
17:39
03/20/23
17:39
SGMA

Sigmatron International

$3.12 /

-0.105 (-3.26%)

In a regulatory 8-K…

In a regulatory 8-K filing, the company states: "On March 2, 2023, SigmaTron Internationalreceived an Event of Default and Reservation of Rights from (i) J.P. Morgan Chase Bank, N.A. dated March 2, 2023 with respect to that certain Amended and Restated Credit Agreement dated as of July 18, 2022, by and among the Company, the other Loan Party thereto, and JPMorgan Chase Bank, N.A., as Lender, and (ii) TCW Asset Management Company, as Administrative Agent dated March 2, 2023 with respect to that certain Credit Agreement date of July 18, 2022 (as amended, restated, supplemented or otherwise modified from time to time, the "Credit Agreement" and together with the Agreement the "Credit Agreements"), by and among the Company, WAGZ, Inc., a Delaware corporation, the financial institutions party thereto from time to time, and TCW Asset Management Company, as Administrative Agent for all Lenders. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Agreement and Credit Agreement, as applicable."

ShowHide Related Items >><<
SGMA Sigmatron International
$3.12 /

-0.105 (-3.26%)

SGMA Sigmatron International
$3.12 /

-0.105 (-3.26%)

Hot Stocks
OpenAI-powered app from Nuance will instantly transcribe patient notes » 17:37
03/20/23
03/20
17:37
03/20/23
17:37
MSFT

Microsoft

$272.20 /

-7.21 (-2.58%)

Nuance Communications, a…

Nuance Communications, a Microsoft Company, announced Dragon Ambient eXperience or DAX Express, a workflow-integrated, fully automated clinical documentation application that is the first to combine proven conversational and ambient AI with OpenAI's newest and most capable model, GPT-4. Extending the proven Dragon Medical portfolio of solutions and building on the market-leading DAX ambient solution launched in 2020, DAX Express is the next milestone in Nuance's long-standing mission to reduce administrative burden and empower clinicians to spend more time taking care of patients and less time on paperwork. .. Using a unique combination of conversational, ambient, and generative AI, DAX Express automatically and securely creates draft clinical notes in seconds for immediate clinical review and completion after each patient visit in the exam room or via telehealth patient conversations. Clinicians will benefit from the seamless capabilities of Dragon Medical One, DAX, and DAX Express, which are tightly integrated into the electronic medical record, beginning from pre-visit through post-encounter, reducing cognitive burdens and helping increase the joy of practicing medicine. "Nuance and Microsoft came together with the goal of helping to digitally transform healthcare, and we are marking the next step forward in the ongoing evolution of AI-powered solutions for overburdened care providers," said Mark Benjamin, CEO of Nuance. "We've taken the power and advanced reasoning capabilities of GPT-4 and integrated it into our proven outcomes-focused AI technologies in a tested and responsible way. Our state-of-the-art blend of conversational, ambient, and generative AI will accelerate the advancement of the care delivery ecosystem beyond what Nuance or Microsoft could have achieved separately - expanding our comprehensive portfolio of solutions that fulfill our vision to improve care quality and support enhanced outcomes for generations to come." Reference Link

ShowHide Related Items >><<
MSFT Microsoft
$272.20 /

-7.21 (-2.58%)

MSFT Microsoft
$272.20 /

-7.21 (-2.58%)

03/20/23 Stifel
Alphabet resumed with a Buy at Stifel
03/20/23 Evercore ISI
Microsoft price target raised to $295 from $280 at Evercore ISI
03/17/23 Mizuho
Microsoft price target raised to $315 from $300 at Mizuho
03/16/23 Macquarie
Microsoft 'clear winner' in ongoing generative AI fight, says Macquarie
MSFT Microsoft
$272.20 /

-7.21 (-2.58%)

MSFT Microsoft
$272.20 /

-7.21 (-2.58%)

MSFT Microsoft
$272.20 /

-7.21 (-2.58%)

MSFT Microsoft
$272.20 /

-7.21 (-2.58%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.